Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452158 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL1388913 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL9961457 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL2452161 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL19170267 | 0.94 | SLC10A2 (0.88) | SLC10A2 | |
| SCHEMBL14666315 | 0.93 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL14666333 | 0.93 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL16743424 | 0.93 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL25274089 | 0.92 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL2843089 | 0.92 | SLC10A2 (0.85) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5910494-A | NOVEL COMPOUNDS THAT REDUCE THE ABSORPTION OF BILE ACIDS FROM THE INTESTINE; FOR PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC CONDITIONS, SUCH AS ATHEROSCLEROSIS | GLAXO WELLCOME INC. (US) | 1999-06-08 | — | — | US | claimed |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11918578-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4245367-A2 | METHODS FOR TREATING CHOLESTASIS | Mirum Pharmaceuticals, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4241840-A2 | METHODS FOR TREATING CHOLESTASIS | Mirum Pharmaceuticals, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230190742-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4137137-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | Satiogen Pharmaceuticals, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220362238-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. | 2022-11-17 | — | — | US | disclosed |
| WO-2010062861-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| CN-1678597-A | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORP (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20230190742-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20220362238-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | SLC10A2 1/4885 |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-11918578-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.